Roy Jacobs & Associates Announces Investigation into Possible Wrongdoing at STAAR Surgical Company (“STAA”)

Roy Jacobs & Associates a law firm representing investors nationwide, is investigating potential claims on behalf of shareholders of STAAR Surgical Co. (“STAAR” or the “Company”) (NASDAQ:STAA) concerning possible breaches of fiduciary duty and securities law violations.

For further information, please contact Roy L. Jacobs, Esq. toll-free at 1-888-884-4490 or by e-mail at rjacobs@jacobsclasslaw.com.

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The investigation is focused on potential breaches of fiduciary duty on the part of the STAAR Board of Directors involving the failure to maintain good manufacturing practices for its products.

On June 30, 2014, the U.S. Food and Drug Administration publicly released a Warning Letter, dated May 21, 2014, concerning an inspection of STAAR's Monrovia Facility which took place from February 10, 2014 to March 21, 2014, stating that there were several regulatory violations at the facility. The Warning Letter noted inadequacies with the manufacture, packing, storage and installation of the Company's implantable lenses and inadequate procedures for documentation, complaints, sterility testing, and record maintenance. The Warning Letter also threatened regulatory action. On this news, the price of STAAR's shares plummeted by over 11%

If you held STAAR shares since prior to April 10, 2014 and continue to hold your shares; and you are interested in discussing your rights or have information relating to this investigation, please contact Roy L. Jacobs. Mr. Jacobs will be glad to personally speak with you at no cost to you.

ROY JACOBS & ASSOCIATESRoy L. Jacobs, Esq., 1-888-884-4490rjacobs@jacobsclasslaw.com

STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Jun 2024 to Jul 2024